Systemic lupus erythematosus is associated with substantial morbidity and involves major organs including the kidneys and the CNS. Based on randomized, controlled trials and long-term ...

Although this is true for many people with iron deficiency, it can be much more complicated. When determining which iron therapy—oral or intravenous (IV)—is right for you, it is important to consider ...

In spite of considerable achievements, treatment of established lupus is a difficult task. Complete remission of mild disease with mucocutaneus or joint disease remains a challenge with a ...

Sodium-cooled fast reactors using metallic-alloy fuel are attracting attention because they are inherently safe and produce more fuel than they use.

A few treatments are known to help clear psoriasis symptoms fast, such as Clobex spray, cyclosporine, and Humria. When choosing a psoriasis treatment, however, also consider other factors like side ...

The rumor mill keeps churning for The Elder Scrolls IV: Oblivion remake. This time around, details about how the remake will significantly improve several gameplay systems have been unearthed.

The Elder Scrolls IV: Oblivion remake is in development, according to a plethora of rumors. And now a new rumor about the the remake has information about a potential release date. It has been 19 ...

Please provide your email address to receive an email when new articles are posted on . Researchers reported improvements at 1 month in OSDI scores, corneal fluorescein staining, and conjunctival ...

Stelara (ustekinumab) is a brand-name injectable drug prescribed for certain autoimmune conditions. Stelara has interactions with some other drugs and certain vaccines. Examples include Orencia ...

Some videos floating on social media show children looking frail, lying in hospital beds with intravenous (IV) drips, surrounded by nervous parents. Some pictures show crowded hospital wards, long ...

There have been many recent rumors of a remaster/remake of The Elder Scrolls IV: Oblivion — including of an imminent reveal and release — though so far there has been no official word from ...

The patient was counseled about the risks of aHSCT, and understood the attendant risks including mortality. The conditioning regimen was one session of plasmapheresis (on day −6); IV rituximab 500 mg ...